Among melanoma pharmacologically targetable genes, in addition to BRAF gene mutations, Ion Torrent called 2 NRAS mutations in different samples as follows: LRG_92/NM_002524.3: c.182A > G p.Gln61Arg and LRG_92/NM_002524.3: c.181C > A p.Gln61Lys with an VAF of 49.9% (6687x) and 64.6% (5642x), respectively. This evidence concerns the gene NRAS and melanoma.